Our Medicines

Learn more about VITRAKVI® by visiting the product website or by downloading prescribing information.

For U.S. residents only.

Loxo Oncology and Bayer are engaged in a collaboration for the development and commercialization of VITRAKVI® (larotrectinib). In the U.S., Bayer and Loxo Oncology are co-promoting VITRAKVI®. This product may not be approved and/or licensed in all countries where this website is accessible.